This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, ...

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Solution: EVERSANA created an AI-enabled omnichannel solution to inform and empower HCPs and patients more effectively. The ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Through a series of position papers, the EFPIA representing brandname drugmakers, self-medication group organisation AESGP, ...

Researchers in the US have shown that an artificial intelligence algorithm trained to analyse video recordings of sleep tests ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...